Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Apr 5, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Carmine Stengone |
Contact Details
Address: 3565 General Atomics Court, Suite 200 San Diego, California 92121 United States | |
| Phone | 858 333 5280 |
| Website | contineum-tx.com |
Stock Details
| Ticker Symbol | CTNM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001855175 |
| CUSIP Number | 21203L104 |
| ISIN Number | US21217B1008 |
| Employer ID | 27-1467257 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carmine N. Stengone MBA, MS | President, Chief Executive Officer and Director |
| Peter T. Slover CPA | Chief Financial Officer |
| Dr. Timothy R. Watkins M.D., M.Sc. | Chief Medical Officer and Head of Development |
| Morgan Paulsen | Senior Manager of Accounting |
| Dr. Daniel S. Lorrain Ph.D. | Chief Science Officer |
| Steve E. Kunszabo | Senior Director of Investor Relations and Corporate Communications |
| John S. Healy | General Counsel and Corporate Secretary |
| Jennifer Patterson | Vice President of Human Resources |
| Austin Chen Ph.D. | Senior Vice President and Head of Research |
| Julie S. Iwashita | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 144 | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 5, 2026 | 10-Q | Quarterly Report |
| May 5, 2026 | 8-K | Current Report |
| May 1, 2026 | 144 | Filing |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |